1. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4-acridinecarboxamide;Baguley;Cancer Res.,1984
2. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule;Fyfe;Cancer Chemother. Pharmacol.,2001
3. A phase II trial of CI-921 in advanced malignancies;Sklarin;Investig. New Drugs,1992
4. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis;Powis;Cancer Res.,1983
5. Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury;Curtit;Anticancer Res.,2012